A National Spinal Muscular Atrophy Registry for Real-World Evidence. (4th November 2020)

• Record Type: Journal Article
• Authors: Hodgkinson, Victoria L.; Oskoui, Maryam; Lounsberry, Joshua; M'Dahoma, Saïd; Butler, Emily; Campbell, Craig; MacKenzie, Alex; McMillan, Hugh J.; Simard, Louise; Vajsar, Jiri; Brais, Bernard; Chapman, Kristine M.; Chrestian, Nicolas; Crone, Meghan; Dobrowolski, Peter; Dojeiji, Susan; Dowling, James J.; Dupré, Nicolas; Genge, Angela; Gonorazky, Hernan; Hasal, Simona; Izenberg, Aaron; Johnston, Wendy; Leung, Edward; Lochmüller, Hanns; Mah, Jean K.; Marerro, Alier; Massie, Rami; McAdam, Laura; McCormick, Anna; Melanson, Michel; Mezei, Michelle M.; Nguyen, Cam-Tu E.; O'Connell, Colleen; O'Ferrall, Erin K.; Pfeffer, Gerald; Phan, Cecile; Plamondon, Stephanie; Poulin, Chantal; Rodrigue, Xavier; Schellenberg, Kerri L.; Selby, Kathy; Sheriko, Jordan; Shoesmith, Christen; Smith, Garth; Taillon, Monique; Taylor, Sean; Warman Chardon, Jodi; Worley, Scott; Korngut, Lawrence;
• Is Part Of: Canadian journal of neurological sciences. Volume 47:Number 6(2020)
• Page Start: 810
• Page End: 815
• Publication Date: 2020-11-04
• Subjects: Real-world evidence, -- Spinal muscular atrophy, -- Registry, -- Rare disease; Neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; Electronic journals; 616.8
• DOI: 10.1017/cjn.2020.111
• Languages: English
• ISSNs: 0317-1671

Abstract

ABSTRACT: Background: Spinal muscular atrophy (SMA) is a devastating rare disease that affects individuals regardless of ethnicity, gender, and age. The first-approved disease-modifying therapy for SMA, nusinursen, was approved by Health Canada, as well as by American and European regulatory agencies following positive clinical trial outcomes. The trials were conducted in a narrow pediatric population defined by age, severity, and genotype. Broad approval of therapy necessitates close follow-up of potential rare adverse events and effectiveness in the larger real-world population. Methods: The Canadian Neuromuscular Disease Registry (CNDR) undertook an iterative multi-stakeholder process to expand the existing SMA dataset to capture items relevant to patient outcomes in a post-marketing environment. The CNDR SMA expanded registry is a longitudinal, prospective, observational study of patients with SMA in Canada designed to evaluate the safety and effectiveness of novel therapies and provide practical information unattainable in trials. Results: The consensus expanded dataset includes items that address therapy effectiveness and safety and is collected in a multicenter, prospective, observational study, including SMA patients regardless of therapeutic status. The expanded dataset is aligned with global datasets to facilitate collaboration. Additionally, consensus dataset development aimed to standardize appropriate outcome measures across the network and broader Canadian community. Prospective outcome studies, data use, and analyses are independent of the funding partner. Conclusion: Prospective outcome data collected will provide results on safety and effectiveness in a post-therapy approval era. These data are essential to inform improvements in care and access to therapy for all SMA patients.